Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, pr... Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0516 | 1.10021321962 | 4.69 | 4.85 | 4.06 | 8140 | 4.31940495 | CS |
| 4 | -0.3734 | -7.30009775171 | 5.115 | 5.96 | 4.06 | 7114 | 4.95447966 | CS |
| 12 | -4.3834 | -48.037260274 | 9.125 | 9.625 | 4.06 | 52548 | 7.29533996 | CS |
| 26 | -10.7584 | -69.4090322581 | 15.5 | 17.75 | 4.06 | 75945 | 10.15562158 | CS |
| 52 | -20.0084 | -80.842020202 | 24.75 | 24.75 | 4.06 | 81030 | 12.63872756 | CS |
| 156 | -20.0084 | -80.842020202 | 24.75 | 24.75 | 4.06 | 81030 | 12.63872756 | CS |
| 260 | -20.0084 | -80.842020202 | 24.75 | 24.75 | 4.06 | 81030 | 12.63872756 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
